Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
We plan to explore the efficacy and safety of albumin-bound paclitaxel+carboplatin+Camrelizumab combined/not combined with bevacizumab in neoadjuvant therapy for early TNBC patients, optimize the administration method and drug combination therapy.
Epistemonikos ID: 20469bcf9a48665c43695040e4b9ddc3016d970f
First added on: Mar 27, 2025